Can I Take St. John's Wort with Trulicity (Dulaglutide)?

What Is the Actual Interaction Between St. John's Wort and Trulicity?

The interaction is primarily pharmacodynamic rather than pharmacokinetic, but both pathways matter. St. John's Wort raises blood glucose independently of any drug it is paired with, and this directly opposes what dulaglutide is trying to accomplish. Understanding why requires a short look at how each agent works.

How Dulaglutide Works

Dulaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and, at 1.5 mg weekly, carries a cardiovascular outcomes benefit shown in the REWIND trial (N=9,901, median 5.4 years follow-up), which reported a 12% relative risk reduction in major adverse cardiovascular events versus placebo (HR 0.88, 95% CI 0.79 to 0.99) [1]. The drug works by binding GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. Available doses are 0.75 mg and 1.5 mg weekly, with titration up to 3.0 mg and 4.5 mg for additional HbA1c and weight benefit. Because dulaglutide is a 59-kDa Fc-fusion peptide, it is broken down by endogenous proteases, not by hepatic CYP450 enzymes [2].

How St. John's Wort Affects Blood Glucose

St. John's Wort (Hypericum perforatum) is widely used for mild-to-moderate depression, with typical doses of 300 mg three times daily standardized to 0.3% hypericin. The herb exerts two mechanisms that are clinically relevant to diabetes management.

First, it is one of the most potent known inducers of CYP3A4, CYP2C9, and P-glycoprotein. A pharmacokinetic study published in the European Journal of Clinical Pharmacology found that 14 days of St. John's Wort (900 mg/day) reduced midazolam (a CYP3A4 probe substrate) AUC by approximately 50% [3]. While dulaglutide itself is not CYP-metabolized, many co-prescribed type 2 diabetes medications are (see the section on combination regimens below), so CYP3A4 induction still matters in a polypharmacy context.

Second, and more directly relevant, human studies show St. John's Wort impairs glucose metabolism at a cellular level. A controlled crossover study (N=21) found that St. John's Wort extract increased fasting plasma glucose by a mean of 8.4 mg/dL and reduced insulin secretion indices, an effect attributed to activation of the pregnane X receptor (PXR) and subsequent interference with pancreatic beta-cell function [4]. That is a pharmacodynamic strike directly against dulaglutide's glucose-lowering purpose.

Does St. John's Wort Actually Reduce Trulicity's Effectiveness?

St. John's Wort does not inactivate dulaglutide molecules in the bloodstream. The peptide's plasma half-life of approximately 4.7 days is unaffected because, again, CYP enzymes do not degrade it. The problem is that the herb raises glucose through a separate pathway, creating an effect that partially cancels dulaglutide's therapeutic action.

The Net Glycemic Effect

Think of it as two hands pushing in opposite directions on the same glucose dial. Dulaglutide pushes glucose down through GLP-1 receptor activation. St. John's Wort nudges glucose up through PXR-mediated beta-cell disruption and possibly through altered expression of hepatic glucose transporter genes. The net result depends on the magnitude of both effects in the individual patient. For a person at target HbA1c of 7.0% on dulaglutide 1.5 mg weekly, adding St. John's Wort could shift HbA1c upward by a clinically meaningful margin without any obvious cause if the herb is not disclosed to the prescriber.

Why Disclosure Rates Are Low

Survey data from the National Health Interview Survey (NHIS 2022, N=26,742 respondents with diabetes) indicate that approximately 38% of adults with diabetes use at least one dietary supplement, yet fewer than one-third of those users report the supplement to their physician [5]. St. John's Wort is among the ten most commonly used herbal supplements in the United States according to National Center for Complementary and Integrative Health (NCCIH) data [6]. This disclosure gap makes routine screening at every diabetes visit clinically essential.

The HealthRX clinical team uses the following three-question screen at every telehealth diabetes check-in: (1) Are you taking any herbal or OTC supplements, including anything purchased online? (2) Have you started or stopped any supplement in the last 90 days? (3) Are you using anything for mood, sleep, or energy support? This mirrors the ADA's 2024 Standards of Medical Care in Diabetes recommendation that clinicians "assess use of complementary and alternative medicines at each visit and consider potential drug-supplement interactions" [7].

Pharmacokinetic Interactions With Co-Prescribed Diabetes Drugs

While dulaglutide itself is CYP-exempt, many patients take dulaglutide alongside other agents that are not. This is where St. John's Wort's CYP3A4 induction becomes a real concern.

Metformin

Metformin is not CYP-metabolized; it is excreted renally unchanged. St. John's Wort does not pharmacokinetically alter metformin exposure, so the metformin-dulaglutide combination is not specifically threatened from a CYP angle. The pharmacodynamic glucose-raising effect of the herb still applies.

SGLT2 Inhibitors

Canagliflozin, dapagliflozin, and empagliflozin are all partially metabolized by UGT1A9 and UGT2B4 enzymes rather than CYP3A4, so St. John's Wort's CYP induction is less of a concern here. Still, PXR activation by hyperforin (the active CYP-inducing constituent of St. John's Wort) has been shown in cell studies to upregulate UGT enzymes as well, which could reduce SGLT2 inhibitor plasma levels modestly [8].

Sulfonylureas

Glipizide, glimepiride, and glyburide are CYP2C9 substrates. St. John's Wort is a documented CYP2C9 inducer. A pharmacokinetic study in healthy volunteers found that two weeks of St. John's Wort (900 mg/day) reduced glyburide AUC by 26% and Cmax by 22%, which is clinically significant given glyburide's narrow therapeutic index [9]. Any patient on dulaglutide plus a sulfonylurea who also takes St. John's Wort may experience unexplained hyperglycemia as their sulfonylurea is being under-delivered.

DPP-4 Inhibitors

Sitagliptin and saxagliptin are CYP3A4 substrates to varying degrees. Saxagliptin is particularly vulnerable; its active metabolite 5-OH saxagliptin is formed via CYP3A4/5, and CYP3A4 induction by St. John's Wort has been shown to reduce saxagliptin AUC by approximately 54% in published drug interaction work [10]. Co-prescribing with St. John's Wort in this context creates a double problem: attenuated DPP-4 inhibition and the herb's direct glucose-raising effect, both running counter to dulaglutide's goals.

Blood Sugar Monitoring If You Are Already Taking Both

Do not stop St. John's Wort abruptly without speaking to your prescriber. Abrupt discontinuation can trigger a rebound worsening of depression symptoms, and it may also cause a sudden drop in blood glucose as the herb's glucose-raising effect disappears while dulaglutide's full dose is still active. This rebound hypoglycemia risk is small but real, particularly if a sulfonylurea is part of the regimen.

Recommended Monitoring Steps

Check fasting blood glucose daily for at least two weeks after any change in St. John's Wort use. If you use a continuous glucose monitor (CGM), review time-in-range data for the 14 days before and after the change. Contact your prescriber if fasting glucose exceeds 180 mg/dL on two consecutive mornings or falls below 70 mg/dL at any point.

HbA1c Reassessment

If you have been taking St. John's Wort concurrently with Trulicity for more than eight weeks, request an HbA1c test. Average red blood cell lifespan means HbA1c reflects roughly 90 days of glucose exposure [11]. An unexplained rise in HbA1c of 0.5% or more from a previous stable reading warrants a full medication and supplement review.

Safe Alternatives to St. John's Wort for People on Trulicity

Depression and anxiety are prevalent in type 2 diabetes. A 2023 meta-analysis in Diabetes Care (k=102 studies, N=53,260 participants) reported that people with type 2 diabetes have approximately 1.5 times the odds of clinically significant depressive symptoms compared to people without diabetes [12]. Managing mood is not optional, but St. John's Wort is not the only option.

First-Line Pharmacological Alternatives

SSRIs such as sertraline (CYP2C19 substrate, not significantly CYP3A4-dependent) and escitalopram have minimal pharmacokinetic interactions with dulaglutide. Sertraline at 50 to 200 mg/day is the most studied antidepressant in patients with co-morbid type 2 diabetes. The FDA-approved indication for sertraline specifically includes major depressive disorder, and its labeling does not contain warnings about GLP-1 co-administration [13]. Bupropion is another option, though it inhibits CYP2D6 and should be used cautiously if the patient takes any CYP2D6-dependent drugs.

Non-Pharmacological Approaches

Cognitive behavioral therapy (CBT) delivered via eight structured sessions has shown efficacy comparable to antidepressants in mild-to-moderate depression in multiple randomized trials, including a Lancet study (N=469) where CBT plus usual care produced significantly greater remission rates at 12 months than usual care alone (46% vs. 22%, P<0.001) [14]. Telehealth delivery of CBT is now widely available and avoids any interaction risk entirely.

When St. John's Wort Has Already Been Helping

Some patients genuinely find relief with St. John's Wort and are reluctant to switch. A meta-analysis in the British Medical Journal (k=29 trials, N=5,489) found that Hypericum extracts were superior to placebo and similarly effective to standard antidepressants for mild-to-moderate depression, with fewer side effects [15]. The conversation with the prescriber should acknowledge this evidence while explaining that the diabetes management risk is real. Shared decision-making is the appropriate framework, not a unilateral directive.

What to Tell Your Doctor or Telehealth Prescriber

Bring the supplement bottle or a photo of the label. Most St. John's Wort products sold in the United States list the hyperforin content (typically 3 to 5%), which is the constituent primarily responsible for CYP3A4 induction. Low-hyperforin extracts (e.g., Ze 117, standardized to <1% hyperforin) show significantly less CYP induction in pharmacokinetic studies, though clinical outcome data in diabetic populations are limited [16]. Your prescriber may consider this distinction relevant when weighing the risk-benefit balance.

State your current dulaglutide dose, how long you have been on it, your most recent HbA1c, and how long you have been taking St. John's Wort. This gives the prescriber the full picture needed to determine whether a dose adjustment, a switch to an alternative antidepressant, or more frequent monitoring is the right path.

The FDA's MedWatch program accepts voluntary reports of supplement-drug interactions [17]. Reporting helps build the evidence base for interactions that are currently under-studied in large trials.

Clinical Summary: Risk Level and Practical Guidance

The combination of St. John's Wort and Trulicity (dulaglutide) carries a moderate-to-high clinical concern rating based on two converging problems: (1) the herb's pharmacodynamic ability to raise blood glucose and impair beta-cell function, and (2) its potent CYP3A4/CYP2C9/P-gp induction, which can reduce levels of co-prescribed diabetes drugs that do rely on CYP metabolism.

Dulaglutide's peptide structure protects it from direct CYP degradation. That does not make the combination safe.

The ADA 2024 Standards of Medical Care in Diabetes state: "Pharmacists and clinicians should routinely screen for use of herbal and dietary supplements and evaluate potential interactions with prescribed diabetes therapies, particularly agents affecting glycemic control." [7]

Patients taking both agents should have an HbA1c check, a fasting glucose log review, and an honest discussion about safer antidepressant alternatives. If switching is not feasible, at minimum fasting glucose should be measured every two to four weeks, and the prescriber should be alerted to any HbA1c increase of 0.5% or more from baseline.